TRILIPIX: Co-promotion Abbot con Astra Zeneca

AstraZeneca will help Abbott reach more physicians with its Trilipix (fenofibric acid) drug, a cholesterol product approved by FDA last December.

The companies also announced an NDA submission for Certriad, a Trilipix/Crestor combination. Abbott and AstraZeneca teamed up last August to co-promote Crestor.

“We're two separate companies that have relationships with different physicians,” said Donna Huang, a spokesperson for AstraZeneca, adding that the co-promotion will “help Abbott increase the share of voice [for Trilipix], as well as reach out to new physicians.” Huang declined to give the specifics on sales rep relegations between the two companies.

Mas...